糖尿病の流行の増加:デンマークの薬学疫学データベースからの証拠

Henrik Støvring¹, Morten Andersen, Henning Beck-Nielsen

¹Research Unit of General Practice, University of Southern Denmark, DK-5000, Odense, Denmark. hstovring@health.sdu.dk <hstovring@health.sdu.dk>

Lancet (London, England)

|August 23, 2003

まとめ

糖尿病の罹患率は世界中で増加しています. しかし,デンマークの研究によると,治療を受けた糖尿病患者の死亡率は1993年から現在まで減少しており,症例数が増加しているにもかかわらず減少しています.

科学分野:

エピデミオロジーエピデミオロジー
公衆衛生は公衆衛生である.
エンドクリノロジーエンドクリノロジー

背景:

世界の糖尿病の罹患率は増加しており,流行を理解するために疫学的な研究が必要である.
薬剤で治療される糖尿病は,流行,発生,死亡率を注意深く監視する必要があります.
コミュニティベースの研究は,正確な健康傾向分析に不可欠です.

研究の目的:

特定地域における薬物治療による糖尿病の流行病学的分析を行う.
デンマークのフィン郡における糖尿病の流行,発生,死亡率を推定する.
時間の経過とともに糖尿病の傾向を分析し,これらの傾向に影響を与える要因を特定する.

主な方法:

デンマークのフィーン郡の47万人の人口の流行病学的分析.
研究期間中に薬剤で治療された糖尿病のすべての患者を含む.
流行,発生,死亡データに関する統計分析.

主要な成果:

糖尿病の罹患率は,女性 (OR 1.026) と男性 (OR 1.041) の両方で有意に増加しました.
治療を受けた糖尿病患者の死亡率は,女性 (RR 0.976) と男性 (RR 0.966) の両方で減少しました.
研究期間中,糖尿病の発生率の明確な傾向は認められなかった.

結論:

糖尿病の罹患率の増加は,治療を受けた個人の死亡率の増加と必ずしも相関しているわけではありません.
治療を受けた糖尿病患者の死亡率の減少は,ライフスタイル要因に関する将来の研究において考慮されるべきである.
ライフスタイル,糖尿病の蔓延率の上昇,死亡率の傾向との複雑な関係を理解するために,さらなる調査が必要である.

さらに関連する動画

08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

関連する概念動画

01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...

01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

関連する実験動画